Revvity Inc. (RVTY)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Revvity Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 112.50 $ — 85% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -4.8% failed
- More than 10% revenue growth is expected for the coming year 5.2% failed
- Share count grows by less than 3% a year -3.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 21.5% failed
- Gross margin at 40% or higher and without meaningful erosion 53.1% passed
- Goodwill from acquisitions does not grow faster than revenue 54.4% failed
- Net debt below twice EBITDA 3.9 x EBITDA failed
- Operating cash flow covers the profits of the last three years 882 m passed
- Return on capital at 15% or higher, or up versus two years ago 3.3% failed
- Insiders hold at least 10% or are net buyers 0.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 4.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 19
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5.25 | 5.21 – 5.29 | 2,830 | 3.8% | 10 |
| 12/31/2027 | 5.83 | 5.71 – 6.09 | 2,981 | 11.1% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.23 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.78 | -6.10 | 729 | 4.80 | 13.00 | 174 | 150 |
| 2025: Q1 | 0.35 | 56.50 | 665 | 2.30 | 6.40 | 128 | 112 |
| 2025: Q2 | 0.47 | -26.70 | 720 | 4.10 | 7.70 | 134 | 116 |
| 2025: Q3 | 0.40 | -48.10 | 699 | 2.20 | 6.70 | 139 | 120 |
| 2025: Q4 | 0.87 | 11.20 | 772 | 5.90 | 12.70 | 183 | 163 |
| 2026: Q1 | 0.36 | 3.60 | 711 | 7.00 | 5.70 | 115 | 95 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2,116 | 306 | 234 | 2.12 | 351 | 2,154 | 4,277 |
| 2017 | 2,257 | 305 | 113 | 1.02 | 288 | 2,503 | 6,091 |
| 2018 | 2,778 | 371 | 239 | 2.14 | 311 | 2,585 | 5,976 |
| 2019 | 2,884 | 405 | 228 | 2.04 | 363 | 2,814 | 6,539 |
| 2020 | 3,783 | 1,020 | 728 | 6.50 | 892 | 3,735 | 7,960 |
| 2021 | 3,828 | 1,340 | 943 | 8.08 | 1,411 | 7,141 | 15,001 |
| 2022 | 3,312 | 781 | 569 | 4.50 | 680 | 7,383 | 14,130 |
| 2023 | 2,751 | 399 | -118 | -0.95 | 91 | 7,873 | 13,565 |
| 2024 | 2,755 | 411 | 296 | 2.41 | 628 | 7,667 | 12,392 |
| 2025 | 2,856 | 357 | 242 | 2.13 | 582 | 7,250 | 12,168 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Revvity, Inc. bietet Lösungen, Technologien und Dienste für die Gesundheitswissenschaften an.
| Employees | 11,000 |
|---|---|
| Headquarters | Waltham, MA |
| Address | 77 4th Avenue, 02451 Waltham, United States |
| Phone | 781 663 6900 |
| Website | revvity.com |
| IPO Date | 6. Apr 1983 |
| ISIN | US7140461093 |
| Stock Split | 2:1 on 06/04/2001 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Prahlad R. Singh Ph.D. | CEO, President & Director | 1965 |
| Maxwell Krakowiak | Senior VP & CFO | 1990 |
| Tajinder S. Vohra | Senior Vice President of Global Operations | 1966 |
| Joel S. Goldberg | Senior VP of Administration, General Counsel & Secretary | 1969 |
| Miriame Victor | Senior Vice President & Chief Business Officer | 1981 |
| Anita Gonzales | Chief Accounting Officer, VP & Controller | 1976 |
| Bryan A. Kipp | Senior VP of Technology & Licensing | – |
| Madhuri Hegde FACMG, Ph.D. | Senior VP & Chief Scientific Officer | – |
| Stephen Barr Willoughby | Senior VP of Investor Relations & Head of ESG | – |
| Magali Four | Senior VP and Chief People & Culture Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Jul 2026 | Gonzales Anita | Vice President and CAO | Sell | 85 | 109.48 | 9,306 |
| 20. Apr 2026 | Anita Gonzales | CAO | Sell | 80 | 92.80 | 7,424 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.